Specialized care for localized and advanced prostate cancer with PSA monitoring, androgen deprivation therapy, and novel treatments for castration-resistant disease.
Expert management of prostate cancer from localized disease to metastatic castration-resistant prostate cancer (mCRPC). We specialize in PSA monitoring, androgen deprivation therapy, novel hormonal agents, and chemotherapy for advanced disease.
Prostate-specific antigen testing, PSA velocity, and PSA doubling time for diagnosis and treatment monitoring.
Transrectal ultrasound-guided biopsy with Gleason grading and Grade Group classification for risk stratification.
Decipher, Oncotype DX, and other genomic tests to guide treatment decisions and predict outcomes.
Weak stream, difficulty starting/stopping, frequent urination (especially at night), urgency.
Blood in urine/semen, painful ejaculation, pelvic discomfort or bone pain in advanced stages.
Unexplained weight loss, fatigue; often asymptomatic in early stages.
Risk rises after 50; higher with first-degree relative affected or African ancestry.
BRCA1/2, HOXB13 mutations; hereditary prostate cancer syndromes.
Obesity, high-fat diet, sedentary lifestyle, smoking may increase risk.
Regular PSA testing and imaging studies to monitor treatment response and disease progression.
Collaboration with urologists, radiation oncologists, and other specialists for comprehensive care.
Managing treatment side effects and maintaining quality of life throughout the treatment journey.